Analyst Ratings For Aclaris Therapeutics Inc (NASDAQ:ACRS)
Today, Cantor Fitzgerald reiterated its Buy rating on Aclaris Therapeutics Inc (NASDAQ:ACRS) with a price target of $50.00.
There are 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Aclaris Therapeutics Inc (NASDAQ:ACRS) is Buy with a consensus target price of $45.3333 per share, a potential 667.06% upside.
Some recent analyst ratings include
- 3/15/2019-Aclaris Therapeutics Inc (NASDAQ:ACRS) had its Buy rating reiterated by Cantor Fitzgerald with a $50.00 price target
- 2/8/2018-Aclaris Therapeutics Inc (NASDAQ:ACRS) has coverage initiated with a Buy ➝ Buy rating and $53.00 price target
- 7/31/2017-Aclaris Therapeutics Inc (NASDAQ:ACRS) had its Buy rating reiterated by Jefferies Financial Group with a $36.00 price target
- On 10/22/2018 Anand Mehra, Director, bought 372,093 with an average share price of $10.75 per share and the total transaction amounting to $3,999,999.75.
- On 10/4/2018 Stephen A Tullman, Director, bought 7,100 with an average share price of $14.00 per share and the total transaction amounting to $99,400.00.
- On 8/23/2018 Stephen A Tullman, Director, bought 6,600 with an average share price of $15.00 per share and the total transaction amounting to $99,000.00.
- On 8/15/2018 Stephen A Tullman, Director, bought 6,250 with an average share price of $15.97 per share and the total transaction amounting to $99,812.50.
- On 6/12/2018 Kamil Ali-Jackson, Insider, sold 5,000 with an average share price of $20.00 per share and the total transaction amounting to $100,000.00.
- On 5/18/2018 Kamil Ali-Jackson, Insider, sold 10,000 with an average share price of $20.00 per share and the total transaction amounting to $200,000.00.
- On 5/16/2018 Andrew Kenneth William Powell, Director, bought 500 with an average share price of $19.12 per share and the total transaction amounting to $9,560.00.
About Aclaris Therapeutics Inc (NASDAQ:ACRS)
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research. Its lead product is ESKATA, a hydrogen peroxide topical solution that has completed Phase III clinical trials for the treatment of raised seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101, a hydrogen peroxide topical solution, which has completed Phase II clinical trials for the treatment of common warts. In addition, it is developing JAK inhibitors, including ATI-501, which is in Phase II clinical trials for the oral treatment of alopecia totalis and alopecia universalis; and ATI-502 that is in Phase II clinical trials for the topical treatment of patchy autoimmune dermatologic condition, vitiligo, androgenetic alopecia, and loss of eyebrow hair. Further, the company provides contract research services, such as laboratory services under contract research arrangements to pharmaceutical and biotech companies; and discovers and develops kinase inhibitors to treat inflammatory and immunological disorders and cancer. It has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Recent Trading Activity for Aclaris Therapeutics Inc (NASDAQ:ACRS)
Shares of Aclaris Therapeutics Inc closed the previous trading session at 5,91 −0,020 0,34 % with 469400 shares trading hands.
